All In Biotech

Drug Trial Radar · NCT07937553

Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.

An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 15, 2025

Primary completion

Aug 1, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Kidney Cancer Research BureauAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC. Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup. These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.

Conditions

  • Metastatic Chromophobe Renal Cell Carcinoma

Interventions

  • LenvatinibDrug

    tablets

  • PembolizumabDrug

    solution

  • everolimusDrug

    tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: 12 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

    Chelyabinsk, Russia · Recruiting

  • V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University

    Krasnoyarsk, Russia · Recruiting

  • Orenburg Regional Cancer Center

    Orenburg, Russia · Recruiting

  • Dr. Berezin Medical Institute

    Saint Petersburg, Russia · Recruiting

  • SBHI Leningrad regional clinical hospital, Saint-Petersburg

    Saint Petersburg, Russia · Recruiting

  • Saratov Regional Cancer Center

    Saratov, Russia · Recruiting

  • Republican Clinical Oncology Dispensary

    Ufa, Russia · Recruiting

  • Sverdlovskiy Regional Oncological Dispensary

    Yekaterinburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.